当前蛋白身份:P02649 重新检索
本组结构的主要差异维度
构建体不同 突变/修饰不同 组装状态不同 配体/离子不同 实验方法不同 实验环境不同 结构质量指标不同

差异标签只比较当前检索结果;所有PDB和assembly原始记录仍分别保留。

相关结构差异明细

一行代表一个 PDB 条目中的一个 biological assembly;同一蛋白的多个单体会分别列出。

PDB 条目 Assembly / 聚集状态 构建体 突变与修饰 配体、离子与非聚合物 实验方法 实验环境 结构质量
1B68 APOLIPOPROTEIN E4 (APOE4), 22K FRAGMENT 提交 1999-01-21 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 19–209(191 aa) 片段:22K FRAGMENT, ISOFORM E4, RECEPTOR BINDING DOMAIN, RESIDUES 1-191
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6;298 K;WELL : 28% PEG 400, 20MM NAOAC, PH 6.0, 0.1% BME PROTEIN SOLN: 40MM (NH4)H(CO3), 7MG/ML PROTEIN DROPS : WELL/PROTEIN 1/3, ROOM TEMPERATURE, pH 6.00, VAPOR DIFFUSION, HANGING DROP, temperature 298K
分辨率 2.00 Å R-free 0.255
1BZ4 APOLIPOPROTEIN E3 (APO-E3), TRUNCATION MUTANT 165 提交 1998-11-05 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 40–183(144 aa) 片段:22K FRAGMENT, RECEPTOR BINDING DOMAIN, RESIDUES 1-165, TRUNCATION AT RESIDUE 165
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 pH 5.6;RT, 50MM NA-CACODYLATE, PH 5.6, 20-25% PEG 400, 1% 2-ME. NOTE : W/O 2-ME, ANOTHER ORTHORHOMBIC FORM APPEARS (SEE PDB ENTRY 1oR2).
分辨率 1.85 Å R-free 0.245
1EA8 Apolipoprotein E3 22kD fragment LYS146GLU mutant 提交 2001-07-11 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 19–209(191 aa) 片段:RECEPTOR BINDING DOMAIN, RESIDUES 1-191
突变:YES 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 pH 5.6;50MM NA-CACODYLATE, PH 5.6, ORTHORHOMBIC FORM ORTHO-2 APPEARS (SEE PDB ENTRY 1OR2).
分辨率 1.95 Å R-free 0.258
1GS9 Apolipoprotein E4, 22k domain 提交 2002-01-02 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 19–183(165 aa) 片段:RECEPTOR BINDING DOMAIN, RESIDUES 1-165
突变:YES 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 pH 5.6;50MM NA-CACODYLATE, PH 5.6, 20-25% PEG 400, 1% 2-ME, RT, CRYSTALLIZED FROM FULL LENGTH APOE4 CONSTRUCT (299 RESIDUES). PROTEOLYTIC CLEAVAGE IN CRYSTALLIZATION DROP TO 22K FRAGMENT. NEW, THIRD ORTHOGONAL CRYSTAL FORM OF APOE (ORTHO-3)
分辨率 1.70 Å R-free 0.247
1H7I Apolipoprotein E3 22kD fragment LYS146GLN mutant 提交 2001-07-08 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 19–209(191 aa) 片段:RECEPTOR BINDING DOMAIN, RESIDUES 1-191
突变:YES 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 pH 5.6;50MM NA-CACODYLATE, PH 5.6, 20-25% PEG 400, 1% 2-ME. RT. ORTHORHOMBIC FORM ORTHO-2 APPEARS (SEE PDB ENTRY 1OR2).
分辨率 1.90 Å R-free 0.259
1LE2 STRUCTURAL BASIS FOR ALTERED FUNCTION IN THE COMMON MUTANTS OF HUMAN APOLIPOPROTEIN-E 提交 1991-08-22 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 41–184(144 aa)
未记录 未记录非水小分子 X-RAY DIFFRACTION mmCIF 未提供已读取条件 分辨率 3.00 Å
1LE4 STRUCTURAL BASIS FOR ALTERED FUNCTION IN THE COMMON MUTANTS OF HUMAN APOLIPOPROTEIN-E 提交 1991-08-22 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 41–184(144 aa)
未记录 未记录非水小分子 X-RAY DIFFRACTION mmCIF 未提供已读取条件 分辨率 2.50 Å
1LPE THREE-DIMENSIONAL STRUCTURE OF THE LDL RECEPTOR-BINDING DOMAIN OF HUMAN APOLIPOPROTEIN E 提交 1991-08-22 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 41–184(144 aa)
未记录 未记录非水小分子 X-RAY DIFFRACTION mmCIF 未提供已读取条件 分辨率 2.25 Å
1NFN APOLIPOPROTEIN E3 (APOE3) 提交 1996-07-17 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 19–209(191 aa) 片段:22KD RECEPTOR BINDING DOMAIN
未记录 未记录非水小分子 X-RAY DIFFRACTION mmCIF 未提供已读取条件 分辨率 1.80 Å R-free 0.259
1NFO APOLIPOPROTEIN E2 (APOE2, D154A MUTATION) 提交 1996-07-17 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 19–209(191 aa) 片段:22KD RECEPTOR BINDING DOMAIN
突变:D154A 未记录非水小分子 X-RAY DIFFRACTION mmCIF 未提供已读取条件 分辨率 2.00 Å R-free 0.270
1OEF PEPTIDE OF HUMAN APOE RESIDUES 263-286, NMR, 5 STRUCTURES AT PH 4.8, 37 DEGREES CELSIUS AND PEPTIDE:SDS MOLE RATIO OF 1:90 提交 1996-03-16 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 281–304(24 aa) 片段:RESIDUES 263 - 286
未记录 未记录非水小分子 SOLUTION NMR
NMR测量条件 pH 4.8;310 K
分辨率未提供
1OEG PEPTIDE OF HUMAN APOE RESIDUES 267-289, NMR, 5 STRUCTURES AT PH 6.0, 37 DEGREES CELSIUS AND PEPTIDE:SDS MOLE RATIO OF 1:90 提交 1996-03-16 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 285–307(23 aa) 片段:RESIDUES 267 - 289
未记录 未记录非水小分子 SOLUTION NMR
NMR测量条件 pH 6;310 K
分辨率未提供
1OR2 APOLIPOPROTEIN E3 (APOE3) TRUNCATION MUTANT 165 提交 1999-03-25 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 19–183(165 aa) 片段:RECEPTOR BINDING DOMAIN, RESIDUES 1-165
突变:TRUNCATION AT RESIDUE 165 非标准单体:是(mmCIF未提供具体位点) 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 5.6;293 K;50MM NA-CACODYLATE, PH 5.6, 10-20% PEG 400 AT ROOM TEMPERATURE. NO 2-ME ADDED. NOTE: WITH 2-ME OR LOWER PEG CONCENTRATIONS, OTHER CRYSTAL FORMS APPEARS (SEE PDB ENTRIES 1BZ4, 1OR3), VAPOR DIFFUSION, HANGING DROP, temperature 293K
分辨率 2.50 Å R-free 0.297
1OR3 APOLIPOPROTEIN E3 (APOE3), TRIGONAL TRUNCATION MUTANT 165 提交 1998-12-01 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 19–183(165 aa) 片段:RECEPTOR BINDING DOMAIN
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 pH 5.6;RT, 50MM NA-CACODYLATE, PH 5.6, 10-20% PEG 400, 1% 2-ME. NOTE: W/O 2-ME OR HIGHER PEG CONCENTRATIONS, OTHER CRYSTAL FORMS APPEARS (SEE PDB ENTRIES 1BZ4, 1OR2).
分辨率 1.73 Å R-free 0.238
2KC3 NMR solution structure of complete receptor binding domain of human apolipoprotein E 提交 2008-12-15 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 19–201(183 aa) 片段:UNP residues 19-201
未记录 未记录非水小分子 SOLUTION NMR
NMR测量条件 pH 6.8;303 K;离子强度(mmCIF原始值)0.05;压力 ambient
NMR样品组成 1 mM [U-100% 13C; U-100% 15N; U-70% 2H] Human apolipoprotein E N-terminal domain-1, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR样品组成 1 mM [U-100% 13C; U-100% 15N; U-30% 2H] Human apolipoprotein E N-terminal domain-2, 95% H2O/5% D2O | 95% H2O/5% D2O
分辨率未提供
2KNY Fusion construct of CR17 from LRP-1 and ApoE residues 130-149 提交 2009-09-08 Assembly 1 信息不足 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 147–167(21 aa) 片段:Fusion of LRP UNP residues 2770-2817 and Apo-E UNP residues 147-167
未记录 CA CALCIUM ION × 1 SOLUTION NMR
NMR测量条件 pH 7.45;298 K;离子强度(mmCIF原始值)0.15;压力 ambient
NMR测量条件 pH 7.45;298 K;离子强度(mmCIF原始值)0.05;压力 ambient
NMR样品组成 20 mM [U-99% 2H] HEPES-1, 50 mM sodium chloride-2, 3 mM sodium azide-3, 5 mM CALCIUM ION-4, 0.8 mM [U-99% 13C; U-99% 15N] entity_1-5, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR样品组成 20 mM [U-99% 2H] HEPES-6, 50 mM sodium chloride-7, 3 mM sodium azide-8, 5 mM CALCIUM ION-9, 0.8 mM [U-99% 13C; U-99% 15N] entity_1-10, 100% D2O | 100% D2O
NMR样品组成 20 mM [U-99% 2H] HEPES-11, 50 mM sodium chloride-12, 3 mM sodium azide-13, 5 mM CALCIUM ION-14, 0.8 mM [U-99% 15N] entity_1-15, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR样品组成 20 mM [U-99% 2H] HEPES-16, 150 mM sodium chloride-17, 3 mM sodium azide-18, 2 mM [U-99% 2H] EDTA-19, 0.5 mM [U-99% 15N] entity_2-20, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR样品组成 20 mM [U-99% 2H] HEPES-21, 150 mM sodium chloride-22, 3 mM sodium azide-23, 2 mM [U-99% 2H] EDTA-24, 0.5 mM [U-99% 13C; U-99% 15N] entity_2-25, 90% H2O/10% D2O | 90% H2O/10% D2O
分辨率未提供
2L7B NMR Structure of full length apoE3 提交 2010-12-07 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 19–317(299 aa)
未记录 未记录非水小分子 SOLUTION NMR
NMR测量条件 pH 6.9;303 K;离子强度(mmCIF原始值)0.1;压力 ambient
NMR样品组成 1 mM [U-13C; U-15N; U-2H] apoE3, 100 mM sodium phosphate, 10 mM DTT, 5 mM [U-100% 2H] EDTA, 1 mM DSS, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR样品组成 1 mM [U-100% 13C; U-100% 15N; U-50% 2H] apoE3, 10 mM DTT, 1 mM DSS, 5 mM [U-100% 2H] EDTA, 100 mM sodium phosphate, 90% H2O/10% D2O | 90% H2O/10% D2O
分辨率未提供
6IWB Crystal structure of a computationally designed protein (LD3) in complex with BCL-2 提交 2018-12-05 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 41–186(146 aa)
未记录 SO4 SULFATE ION × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;295.15 K;17% PEG2000, 0.1M Sodium Succinate (pH 5.5), 0.32M Ammonium Sulfate
分辨率 2.50 Å R-free 0.275
6IWB Crystal structure of a computationally designed protein (LD3) in complex with BCL-2 提交 2018-12-05 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 C 41–186(146 aa)
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;295.15 K;17% PEG2000, 0.1M Sodium Succinate (pH 5.5), 0.32M Ammonium Sulfate
分辨率 2.50 Å R-free 0.275
6NCN Fragment-based Discovery of an apoE4 Stabilizer 提交 2018-12-11 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 20–181(162 aa)
未记录 KJM 1-(3-chlorophenyl)cyclobutane-1-carboximidamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;296 K;20% w/v Polyethylene glycol monomethyl ether mesylate 5,000; 0.1M Bis-Tris buffer at pH6.5
分辨率 1.82 Å R-free 0.219
6NCO Fragment-based Discovery of an apoE4 Stabilizer 提交 2018-12-11 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 20–181(162 aa)
未记录 KQP 1-[5-chloro-4'-(2-hydroxypropan-2-yl)[1,1'-biphenyl]-3-yl]cyclobutane-1-carboximidamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;296 K;20% w/v Polyethylene glycol monomethyl ether mesylate 5,000; 0.1M Bis-Tris buffer at pH6.5
分辨率 1.71 Å R-free 0.220
6V7M Crystal structure of a proteolytically cleaved, amino terminal domain of apolipoprotein E3 提交 2019-12-08 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 1–100(100 aa) 片段:UNP residues 1-100
链 B 101–183(83 aa) 片段:UNP residues 101-183
未记录 PO4 PHOSPHATE ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 5.8;298 K;Crystallization was by sitting drop vapor diffusion in Cryschem plates at room temperature. Reservoirs were 16% to 18 % 2-methyl-2,4-pentanediol (MPD) buffered with 0.1 M sodium acetate at pH 5.8 and including 0.25% octyl-beta-D-1-thioglucopyranoside. The droplets were initial composed of equal amounts of the reservoir and an 8 mg/ml solution of the protein in 0.02 M ammonium carbonate.
分辨率 2.00 Å R-free 0.260
7FCR Crystal structure of the N-terminal domain of mutants of Human Apolipoprotein-E (ApoE) 提交 2021-07-15 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 19–209(191 aa)
突变:C130I NA SODIUM ION × 2 X-RAY DIFFRACTION
X-ray结晶条件 MICROBATCH;pH 5.15;294 K;100 mM sodium cacodylate, 28% PEG 400
分辨率 1.40 Å R-free 0.194
7FCS Crystal structure of the N-terminal domain of mutants of Human Apolipoprotein-E (ApoE) 提交 2021-07-15 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 19–209(191 aa)
突变:C130V NA SODIUM ION × 3 X-RAY DIFFRACTION
X-ray结晶条件 MICROBATCH;pH 5.15;294 K;100 mM sodium cacodylate, 28% PEG 400
分辨率 1.60 Å R-free 0.216
7UVJ Rationally Designed ED1 Epitope-Scaffold Immunogen for SARS-CoV-2 提交 2022-05-02 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 40–183(144 aa)
未记录 GOL GLYCEROL × 1 PEG DI(HYDROXYETHYL)ETHER × 1 ACT ACETATE ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;300 K;0.2 M sodium formate, 20% w/v PEG3350
分辨率 1.99 Å R-free 0.312
7UVJ Rationally Designed ED1 Epitope-Scaffold Immunogen for SARS-CoV-2 提交 2022-05-02 Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 B 40–183(144 aa)
未记录 GOL GLYCEROL × 1 PEG DI(HYDROXYETHYL)ETHER × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;300 K;0.2 M sodium formate, 20% w/v PEG3350
分辨率 1.99 Å R-free 0.312
8AX8 Human Apolipoprotein E4 (ApoE4) N-terminal domain (space group P3121) 提交 2022-08-31 Assembly 1 信息不足 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 19–317(299 aa)
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.5;293.15 K;HEPES, PEG3350
分辨率 1.55 Å R-free 0.231
8AX9 Human Apolipoprotein E4 (ApoE4) N-terminal domain (space group P212121) 提交 2022-08-31 Assembly 1 信息不足 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 19–317(299 aa)
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.5;293.15 K;HEPES, PEG3350
分辨率 1.55 Å R-free 0.195
8CDY N-terminal domain of human apolipoprotein E 提交 2023-02-01 Assembly 1 信息不足 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 19–317(299 aa)
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;293.15 K;HEPES, PEG 6000
分辨率 1.90 Å R-free 0.231
8CE0 N-terminal domain of human apolipoprotein E 提交 2023-02-01 Assembly 1 信息不足 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 19–317(299 aa)
未记录 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;293.15 K;NaCl, Hepes, PEG 8000
分辨率 1.75 Å R-free 0.215
8GRX APOE4 receptor in complex with APOE4 NTD 提交 2022-09-02 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 41–180(140 aa)
链 C 41–180(140 aa)
未记录 未记录非水小分子 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.4
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 3.00 Å